Disease progression in C9orf72 mutation carriers

被引:31
|
作者
Floeter, Mary K. [1 ]
Traynor, Bryan J. [2 ]
Farren, Jennifer [1 ]
Braun, Laura E. [1 ]
Tierney, Michael [1 ]
Wiggs, Edythe A. [1 ]
Wu, Tianxia [1 ]
机构
[1] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
[2] NIA, NIH, Bethesda, MD 20892 USA
关键词
AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL DEMENTIA; BEHAVIORAL VARIANT; REPEAT EXPANSION; HEXANUCLEOTIDE REPEAT; CLINICAL-TRIALS; RATING-SCALE; ALS; COGNITION; DECLINE;
D O I
10.1212/WNL.0000000000004115
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in C9orf72 mutation carriers (C9+) with varied clinical phenotypes. Methods: Thirty-four unrelated participants with mutations in C9orf72 were enrolled in a prospective natural history study. Participants were classified as asymptomatic, amyotrophic lateral sclerosis (ALS), ALS-familial frontotemporal dementia (FTD), or behavioral-variant FTD by clinical diagnostic criteria. Diagnostic cognitive and motor tests were repeated at 6 and 18 months. The ALSFRS-R, letter fluency, and FBI were administered at baseline and follow-up visits at 6, 12, and 18 months. Results: The clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up. Conclusions: The pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of C9orf72 mutation carriers and asymptomatic carriers. Longitudinal changes in these measures occurred with disease progression in a manner consistent with presenting phenotype.
引用
收藏
页码:234 / 241
页数:8
相关论文
共 50 条
  • [1] Cerebral glucose metabolism in C9orf72 mutation carriers
    Grimmer, T.
    Diehl-Schmid, J.
    Yakushev, I.
    JOURNAL OF NEUROCHEMISTRY, 2016, 138 : 405 - 405
  • [2] Functional Connectivity Alterations in C9ORF72 Mutation Carriers
    Lee, Suzee
    Trujillo, Andrew
    Khazenzon, Anna
    Guo, Cong
    Yokoyama, Jennifer
    Sha, Sharon
    Karydas, Anna
    Fong, Jamie
    Rosen, Howard
    Miller, Bruce
    Seeley, William
    NEUROLOGY, 2013, 80
  • [3] The potential modifier effect of C9orf72 DNA methylation in C9ORF72 carriers
    Laffita-Mesa, J. M.
    Kreidy, C.
    Paucar, M.
    Svenningsson, P.
    MOVEMENT DISORDERS, 2019, 34 : S183 - S183
  • [4] FDG-PET in presymptomatic C9orf72 mutation carriers
    Popuri, Karteek
    Beg, Mirza Faisal
    Lee, Hyunwoo
    Balachandar, Rakesh
    Wang, Lei
    Sossi, Vesna
    Jacova, Claudia
    Baker, Matt
    Shahinfard, Elham
    Rademakers, Rosa
    Mackenzie, Ian R. A.
    Hsiung, Ging-Yuek R.
    NEUROIMAGE-CLINICAL, 2021, 31
  • [5] Longitudinal imaging in C9orf72 mutation carriers: Relationship to phenotype
    Floeter, Mary Kay
    Bageac, Devin
    Danielian, Laura E.
    Braun, Laura E.
    Traynor, Bryan J.
    Kwan, Justin Y.
    NEUROIMAGE-CLINICAL, 2016, 12 : 1035 - 1043
  • [6] Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers
    Frick, Petra
    Sellier, Chantal
    Mackenzie, Ian R. A.
    Cheng, Chieh-Yu
    Tahraoui-Bories, Julie
    Martinat, Cecile
    Pasterkamp, R. Jeroen
    Prudlo, Johannes
    Edbauer, Dieter
    Oulad-Abdelghani, Mustapha
    Feederle, Regina
    Charlet-Berguerand, Nicolas
    Neumann, Manuela
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 : 72
  • [7] Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers
    Petra Frick
    Chantal Sellier
    Ian R. A. Mackenzie
    Chieh-Yu Cheng
    Julie Tahraoui-Bories
    Cecile Martinat
    R. Jeroen Pasterkamp
    Johannes Prudlo
    Dieter Edbauer
    Mustapha Oulad-Abdelghani
    Regina Feederle
    Nicolas Charlet-Berguerand
    Manuela Neumann
    Acta Neuropathologica Communications, 6
  • [8] Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers
    Popuri, Karteek
    Dowds, Emma
    Beg, Mirza Faisal
    Balachandar, Rakesh
    Bhalla, Mahadev
    Jacova, Claudia
    Buller, Adrienne
    Slack, Penny
    Sengdy, Pheth
    Rademakers, Rosa
    Wittenberg, Dana
    Feldman, Howard H.
    Mackenzie, Ian R.
    Hsiung, Ging-Yuek R.
    NEUROIMAGE-CLINICAL, 2018, 18 : 591 - 598
  • [9] Longitudinal changes in network homogeneity in presymptomatic C9orf72 mutation carriers
    Waugh, Rebecca E.
    Danielian, Laura E.
    Shoukry, Rachel F. Smallwood
    Floeter, Mary Kay
    NEUROBIOLOGY OF AGING, 2021, 99 : 1 - 10
  • [10] C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers
    Rizzu, Patrizia
    Blauwendraat, Cornelis
    Heetveld, Sasja
    Lynes, Emily M.
    Castillo-Lizardo, Melissa
    Dhingra, Ashutosh
    Pyz, Elwira
    Hobert, Markus
    Synofzik, Matthis
    Simon-Sanchez, Javier
    Francescatto, Margherita
    Heutink, Peter
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2016, 4 : 37